Forecast Insight: Antidiabetics - Switching to new molecule antidiabetics drives market growth

It expects the antidiabetics market to reach $29 billion, across the seven major markets, by 2017. The growth will be driven by the launch of new drug classes, notably the DPP-IV inhibitors and GLP-1 agonists, and large growth in patient numbers. However, patent expiries of the glitazone (TZDs) class will restrain market growth.

Scope of this report

Description of the competitive landscape in antidiabetics across seven major markets with market definition and overview.

Event-driven updated sales forecasts for 2008-17 across the seven major markets: US, France, Germany, Italy, Spain, UK and Japan.

Analysis of major events and brand dynamics affecting the diabetes market.

Research and analysis highlights

The antidiabetics market in the seven major markets is expected to grow from $18 billion in 2007 to $29 billion in 2017 at a rate of 5% CAGR. Significant unmet needs remain in diabetes fueling a large pipeline. The epidemiological growth of the market, driven by the obesity epidemic and improved diagnosis rates, is further driving the market.

The glitazone class was the major non-insulin antidiabetic therapy in 2007 driven by the Actos and Avandia franchises. Both of these drugs will lose their marketing leading positions following patent expiry in 2011 and 2013. Safety concerns over Avandia remain unresolved and the drug will continue to continue to lose market share.

The incretin mimetics are likely to be the beneficiaries of Avandia's problems and the DPP-IV inhibitors are expected to become the leading non-insulin antidiabetics. GLP-1 agonists are also expected to record significant sales. The two classes will provide over 75% of the sales from newly launched antidiabetics.

Key reasons to read this report

Quantify the future size of the antidiabetics market and identify opportunities for new products.

Learn how product expiries will shape the antidiabetics market.

Understand the barriers to uptake for novel antidiabetic agents, and the implications of recent regulatory reviews.

For more information Kindly visit the website :

Or Contact us on :
Tel No : (+9122 )27578668 , 27579438
Fax: (+9122 )27579131

Address :
Bharat Book Bureau,
207,Hermes Atrium,
Sector-11
P.O Box 54,
CBD Belapur,
Navi Mumbai - 400614.

Article Source: http://articlepowerplant.com

Bharat Book Bureau is the leading market research information aggregator which provides reports, company profiles, newsletters, country info. and online databases for the past twenty years to corporate, consulting firms, academic institutions, government departments, agencies etc., globally, including India. Bharat Book Bureau provides strategic information tools to the executives, business analysts, and knowledge managers that will help them to probe into and support critical, timely business decisions and strategies.It helps global companies to know different market before starting up business / expanding in different countries across the world. www.bharatbook.com is one stop shop for the business intelligence information requirements.

Please Rate this Article

5 out of 54 out of 53 out of 52 out of 51 out of 5 

Not yet Rated